NCT03180593View on ClinicalTrials.gov

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 7, 2017

Primary Completion Date

January 25, 2018

Study Completion Date

January 25, 2018

Conditions
Hypertension ComplicatedHypertrophy, Left VentricularBlood Pressure
Interventions
DRUG

Valsartan 80 mg

Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy

Trial Locations (1)

75006

Trinity Hypertension & Metabolic Research Institute, Carrollton

All Listed Sponsors
collaborator

Allergan Sales, LLC

INDUSTRY

lead

Trinity Hypertension & Metabolic Research Institute

OTHER

NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH | Biotech Hunter | Biotech Hunter